WO2025070707A1 - フレイルを予防、又は改善するためのジアミン、及び/又はポリアミンを含む組成物 - Google Patents

フレイルを予防、又は改善するためのジアミン、及び/又はポリアミンを含む組成物 Download PDF

Info

Publication number
WO2025070707A1
WO2025070707A1 PCT/JP2024/034608 JP2024034608W WO2025070707A1 WO 2025070707 A1 WO2025070707 A1 WO 2025070707A1 JP 2024034608 W JP2024034608 W JP 2024034608W WO 2025070707 A1 WO2025070707 A1 WO 2025070707A1
Authority
WO
WIPO (PCT)
Prior art keywords
polyamine
composition
diamine
decreased
muscle mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/034608
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
洋輔 角田
晋平 伊藤
宇洋 枡屋
有美 細江
周平 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP2025549163A priority Critical patent/JPWO2025070707A1/ja
Publication of WO2025070707A1 publication Critical patent/WO2025070707A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Definitions

  • composition containing a diamine and/or a polyamine for preventing or improving frailty.
  • Diamines are straight-chain fatty acid hydrocarbon compounds with two amines.
  • Polyamines are straight-chain fatty acid hydrocarbon compounds with three or more amines.
  • Diamines and/or polyamines are known to be widely involved in the synthesis of nucleic acids and proteins and in the regulation of enzyme activity (Non-Patent Document 1). It has been reported that the amount of spermidine, one of the polyamines, in urine samples corrected for creatinine concentration is elevated in some cases of kidney cancer and bladder cancer (Non-Patent Document 1).
  • Non-Patent Document 2 shows that polyamines decrease in aged muscles, suggesting a relationship between the decrease in polyamines in muscles and sarcopenia associated with aging. Furthermore, Patent Document 1 discloses a muscle-building agent that contains polyamines and branched-chain amino acids as active ingredients.
  • An object of the present invention is to provide a composition containing a diamine and/or a polyamine for preventing or ameliorating frailty.
  • the present invention includes the following embodiments.
  • Item 1. A composition containing a diamine and/or a polyamine for preventing or improving frailty.
  • Item 2. The composition according to Item 1, wherein the subject of administration is 40 years of age or older.
  • the diamine is at least one selected from the group consisting of putrescine, cadaverine, and 1,3-diaminopropane;
  • the polyamine is at least one selected from the group consisting of spermidine, spermine, caldine, homospermidine, aminopropylcadaverine, thermine, thermospermine, canavalmine, aminopentylnorspermidine, N,N-bis(aminopropyl)cadaverine, homospermine, caldopentamine, homocaldopentamine, caldohexamine, and homocaldohexamine spermidine;
  • Item 2 The composition according to item 1.
  • Item 4. The composition according to Item 1, which is a food composition or a pharmaceutical oral composition.
  • Item 5 is a food composition or a pharmaceutical oral composition.
  • composition according to Item 1 wherein the frailty is accompanied by at least one selected from the group consisting of a decrease in skeletal muscle mass, a decrease in right arm muscle mass, a decrease in left arm muscle mass, a decrease in trunk muscle mass, a decrease in right leg muscle mass, a decrease in left leg muscle mass, a decrease in grip strength, a decrease in back muscle strength, and a decrease in leg strength.
  • a composition containing a diamine and/or a polyamine for preventing or improving frailty can be provided.
  • compositions One embodiment of the present invention relates to a composition for preventing or improving frailty.
  • the composition includes a diamine and/or a polyamine.
  • Frailty is a state of weakness seen in the elderly, and is said to be an intermediate stage between a healthy state and a state requiring nursing care. Frailty is also said to be primarily caused by physical, psychological, and social factors. Therefore, since frailty is not a medical "disease,” the term “assessment” is used in place of the term “diagnosis” when referring to frailty. However, if frailty progresses, it can lead to a state requiring nursing care, such as difficulty walking, being forced to move around in a wheelchair, or becoming bedridden.
  • the progression of frailty can be measured, for example, according to the assessment criteria of Fried et al., if three or more of the following five items are present: weight loss, subjective fatigue, decreased daily activity, weakened physical ability (walking speed), and decreased muscle strength (grip strength), the individual is considered frail; if one or two of these are present, the individual is considered pre-frail; and if none of these are present, the individual is considered healthy or robust.
  • Those who are to be administered the drug may include those who are not suspected of frailty, those who are suspected of frailty, and those who have been determined to be frail.
  • those who are determined to be pre-frail may fall under those who are suspected of frailty.
  • those who are determined to be frail may fall under those who have been determined to be frail.
  • those who are determined to be healthy or robust may fall under those who are not suspected of frailty.
  • the recipients be aged 40 years or older, 50 years or older, 60 years or older, 70 years or older, or 80 years or older.
  • Preventing frailty may include preventing progression to pre-frailty or frailty, and inhibiting progression of pre-frailty or frailty.
  • preventing frailty may include inhibiting decline in muscle mass by region (right leg, left leg), grip strength, and back muscle strength.
  • Improving frailty may include alleviating the pre-frailty or frailty state, or returning it to normal.
  • improving frailty may include increasing muscle mass by region (right leg, left leg), grip strength, and back muscle strength.
  • a diamine is a straight-chain fatty acid hydrocarbon compound having two amines.
  • a polyamine is a straight-chain fatty acid hydrocarbon compound having three or more amines. Examples of diamines include putrescine, cadaverine, 1,3-diaminopropane, and the like, and mixtures thereof.
  • polyamines examples include spermidine, spermine, caldine, homospermidine, aminopropylcadaverine, thermine, thermospermine, canavalmine, aminopentylnorspermidine, N,N-bis(aminopropyl)cadaverine, homospermine, caldopentamine, homocaldopentamine, caldohexamine, homocaldohexamine spermidine, and the like, and mixtures thereof.
  • the diamine and/or polyamine may be added to the composition as a synthesized compound.
  • the diamine and/or polyamine may also be added to the composition as an extract, a composition, or a purified product from an extract derived from a plant containing these compounds.
  • the extract, composition, or purified product from an extract derived from a plant (hereinafter also referred to as "diamine and/or polyamine composition”) may contain natural components other than diamine and/or polyamine, such as sugars such as monosaccharides, oligosaccharides, and polysaccharides, peptides, and proteins.
  • the diamine and/or polyamine composition is referred to as both an aqueous solution and a powder.
  • the "solid content” refers to the solute content excluding water in the diamine and/or polyamine composition (solution) which is an aqueous solution, and includes sugars, peptides, and salts in addition to diamine and/or polyamine.
  • the diamine and/or polyamine composition is a powder
  • the “solid content” refers to the entire diamine and/or polyamine composition which is a powder.
  • plant refers to a plant body or plant tissue
  • processed plant product refers to a product obtained by processing the plant body or plant tissue.
  • And/or means that both are included, or either one of them is acceptable.
  • Various plants and processed plant products can be used, and are not particularly limited. Examples include cucurbits, solanaceae, grasses, cruciferous plants, legumes, mallows, Asteraceae, Chenopodiaceae, legumes, Theaceae, and plant extracts, plant extracts, and processed products thereof.
  • Examples include petunia, torenia, snapdragon, cyclamen, gypsophila, geranium, sunflower, turfgrass, cotton, enoki mushroom, shimeji mushroom, matsutake mushroom, shiitake mushroom, mushrooms, ginseng, agaricus, turmeric, ginseng, citrus fruits, banana, kiwi, fruit juice, rice, wheat, barley, soybean, corn, milo
  • the plant body or plant tissue used for the production of the diamine and/or polyamine composition is not particularly limited, but is preferably a plant body or tissue in the form of a seed or in the process of growth.
  • Examples of the plant body or tissue in the form of a seed or in the process of growth include the whole tree, flower, bud, ovary, fruit, leaf, cotyledon, stem, bud, root, seed, dry seed, embryo, germ, and root.
  • Microorganisms can also be used for the production of the diamine and/or polyamine composition.
  • yeast contains high concentrations of polyamines, and a method for isolating and purifying a polyamine-containing fraction by extracting yeast cells or culture solution with an acid solution has been described (JP Patent Publication 10-52291).
  • the polyamine content of yeasts reported in a patent publication (JP Patent Publication 10-52291) is approximately 13 mg per 100 g of dried cells for Saccharomyces cerevisiae, approximately 23 mg for Saccharomyces diastaticas, and approximately 103 mg for Candida ulitis.
  • rice seeds, rice germs, wheat seeds, wheat germs, wheat embryos, soybean seeds, soybean germs, soybean embryos, soy milk, soybean lees as processed plant products, or combinations thereof can be suitably used, and more preferably wheat seeds, wheat germs, wheat embryos, soybean seeds, soybean germs, or soybean embryos can be used.
  • a process for producing a diamine and/or polyamine composition for example, a process is used in which a plant and/or a processed plant product is immersed in an ethanol solution and allowed to stand or be stirred. This process extracts polysaccharides, polyphenols, and secondary metabolites into ethanol. When grains such as wheat are used as raw materials, the viscosity of the extract in this process is reduced by extracting gluten, which causes an increase in viscosity, and the viscosity of the extract in the next process described below can also be suppressed. In addition, by removing components other than diamine and/or polyamine, the diamine and/or polyamine content per solid content in the final diamine and/or polyamine composition can be improved.
  • the concentration of the ethanol solution in this process is preferably 20% (v/v) or more and 90% (v/v) or less, and more preferably 30% (v/v) or more and 70% (v/v) or less.
  • concentration lower than 20% (v/v) the extraction of polysaccharides, polyphenols, secondary metabolites, etc. is insufficient, the viscosity increases, and the amount of diamines and/or polyamines extracted increases, which is not preferred.
  • concentration higher than 90% (v/v) the extraction efficiency decreases and the solid content of the diamine and/or polyamine composition increases, which is also not preferred.
  • the treatment time varies depending on the amount of extraction, but is preferably 10 minutes or more, more preferably 30 minutes or more, and even more preferably 1 hour or more. If it is shorter than 10 minutes, components other than diamines and/or polyamines in this treatment process may not be sufficiently extracted. There is no upper limit, but it is usually performed for 24 hours or less, preferably 12 hours or less, and even more preferably 6 hours or less.
  • the liquid fraction is separated from the plant residue and precipitate by centrifugation and/or filtration, and the plant residue and precipitate are recovered and subjected to the next step.
  • the process of treating the plant and/or the processed plant product with water refers to a process of soaking the plant and/or the processed plant product in water and extracting a composition containing diamine and/or polyamine from the plant and/or the processed plant product.
  • Water refers to water to which no acid solution or alkaline solution has been added. This process may be left to stand or may be stirred.
  • the treatment time varies depending on the amount of extraction, but is preferably 10 minutes or more, more preferably 30 minutes or more, and even more preferably 1 hour or more. If it is shorter than 10 minutes, a sufficient amount of diamine and/or polyamine composition may not be extracted in this treatment process.
  • the "process of treating a plant and/or a processed plant product under acidic conditions” refers to a process of immersing a plant and/or a processed plant product in an acidic solution of pH 6 or less and extracting an extract containing diamines and/or polyamines by standing and/or stirring. From the viewpoint of reducing the salt concentration of the final composition and preventing corrosion of the stainless steel tank, weak acid conditions are preferable. Specifically, the process is preferably carried out at a pH between 3.0 and 6.0, and more preferably between 4.0 and 6.0. The pH in the present invention is based on the value measured 10 minutes after the addition of the acid or acid solution and standing or stirring.
  • the acidic solution used for treatment under acidic conditions may be at least one acidic solution selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, phosphoric acid, citric acid, lactic acid, propionic acid, butyric acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, benzoic acid, sulfosalicylic acid, and formic acid.
  • hydrochloric acid sulfuric acid, nitric acid, acetic acid, phosphoric acid, citric acid, lactic acid, propionic acid, butyric acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, malic acid, tartaric acid, benzoic acid, sulfosalicylic acid, and formic acid.
  • hydrochloric acid and/or citric acid it is preferable to use an acidic solution of citric acid.
  • the process of treating the plant and/or processed plant product under acidic conditions is carried out by adding an acid or an acid solution and leaving it to stand or stirring once or multiple times.
  • a preferred embodiment of the present invention is a process that includes multiple steps of adding an acid or an acid solution and leaving it to stand or stirring.
  • the amount of acid or acid solution added varies depending on the type and amount of the plant or processed plant product, so in order to add the minimum amount of acid or acid solution, it is better to add it in multiple batches while measuring the pH.
  • the acidic solution reacts with the plant or processed plant product, some neutralization occurs, but by adding the acid or acid solution in small amounts, the corrosiveness of the acidic solution to the stainless steel is mitigated by the neutralization reaction, and the burden on the stainless steel tank is reduced.
  • the treatment time under acidic conditions can be set appropriately depending on the amount of diamine and/or polyamine composition extracted, but is generally preferably 10 minutes or more, more preferably 30 minutes or more, and even more preferably 1 hour or more. If it is shorter than 10 minutes, a sufficient amount of diamine and/or polyamine composition may not be extracted in this treatment step. There is no upper limit, but it is usually 24 hours or less, preferably 12 hours or less, and particularly preferably 6 hours or less. Even if treatment is carried out for 24 hours or more, the amount of diamine and/or polyamine composition extracted will tend to reach saturation, and it is thought that the amount that can be newly extracted thereafter will be limited.
  • the step of treating the plant and/or processed plant product under acidic conditions is preferably carried out after the step of treating the plant and/or processed plant product with water.
  • an acid or acid solution is added to the aqueous solution to create acidic conditions, and a step of treating the plant and/or processed plant product under acidic conditions is then carried out.
  • the present invention includes a process for separating and collecting a liquid fraction.
  • a plant and/or a processed plant product is treated with water under acidic conditions, and then the liquid fraction is separated from plant residues and precipitates by centrifugation and/or filtration, and collected.
  • the collected liquid fraction contains a large amount of diamines and/or polyamines, and becomes a diamine and/or polyamine composition.
  • the present invention includes a step of adjusting the solution under acidic conditions to pH 6.5 to pH 7.5 as necessary. This step can be carried out either before or after the step of separating and collecting the liquid fraction, but it is preferable to carry out this step after the step of separating and collecting the liquid fraction.
  • the pH can be adjusted by adding an alkaline solution, and examples of the alkaline solution include solutions of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, calcium hydroxide, calcium carbonate, barium hydroxide, and ammonia. From the viewpoint of the safety of the salt generated during neutralization to the human body, it is preferable to use sodium hydroxide.
  • the diamine and/or polyamine composition is provided in the form of an aqueous solution or a powder.
  • the diamine and/or polyamine composition powder can be obtained by treating a plant and/or a processed plant product with water under acidic conditions, and then treating the liquid fraction recovered by centrifugation or filtration separation with spray drying or vacuum freeze drying.
  • the composition may be prepared by combining a diamine and/or a polyamine with a carrier or additive.
  • the composition is preferably a food composition or a pharmaceutical composition for oral administration.
  • the carriers and additives used in the preparation of the composition include various types commonly used in ordinary pharmaceuticals depending on the dosage form of the composition, such as excipients, binders, disintegrants, lubricants, colorants, flavorings, odorants, surfactants, etc.
  • carriers may include excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, methylcellulose, glycerin, sodium alginate, and gum arabic; simple syrup, glucose liquid, starch liquid, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, carboxymethylcellulose, shellac, methylcellulose, ethylcellulose, water, ethanol, and potassium phosphate.
  • excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, methylcellulose, glycerin, sodium alginate, and gum arabic
  • simple syrup glucose liquid, starch liquid, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, carboxymethylcellulose, shellac, methylcellulose,
  • Binders such as dry starch, sodium alginate, powdered agar, powdered laminaran, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglyceride stearic acid, starch, and lactose; disintegration inhibitors such as sucrose, stearic acid, cocoa butter, and hydrogenated oil; absorption promoters such as sodium lauryl sulfate; moisturizers such as glycerin and starch; adsorbents such as starch, lactose, kaolin, bentonite, and colloidal silicic acid; lubricants such as refined talc, stearates, powdered boric acid, and polyethylene glycol.
  • disintegrants such as dry starch, sodium alginate, powdered agar, powdered laminaran, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium
  • tablets include oral tablets (plain tablets, sugar-coated tablets, gelatin-coated tablets, enteric-coated tablets, film-coated tablets, double-layered tablets, multi-layered tablets, etc.), chewable tablets (including those taken by chewing in the mouth), buccal tablets (including those taken after dissolving in the mouth, such as troches), sublingual tablets, and buccal tablets.
  • the following carriers can be used: excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oil, kaolin, talc, etc.; binders such as powdered gum arabic, powdered tragacanth, gelatin, etc.; disintegrants such as laminaran, agar, etc.
  • the capsule is prepared by mixing the active ingredient with the various carriers listed above and filling a hard or soft capsule, etc.
  • the compound or preparation When the compound or preparation is a liquid, it need only be in a liquid form, and may be an aqueous or oily suspension, solution, syrup, elixir, or drink.
  • the liquid is prepared in the usual manner using ordinary additives. There are no limitations on the container in which the liquid is filled, so long as it can be sealed, and glass, aluminum, and plastic containers may be used.
  • the amount of the composition to be ingested can be 0.1 mg/day to 10 mg/day, preferably 0.3 mg/day to 5 mg/day, more preferably 0.5 mg/day to 3 mg/day, calculated as the amount of diamine and/or polyamine per adult.
  • the composition is preferably ingested 2 to 3 times per day.
  • the composition can be ingested, for example, every day, every 2nd day, every 3rd day, every 4th day, every 5th day, every week, every 2 weeks, every 3 weeks, or every 4 weeks. It is preferable to ingest the composition every day.
  • the amount of the composition to be ingested can be 0.08 mg/day to 8 mg/day, preferably 0.24 mg/day to 4 mg/day, more preferably 0.4 mg/day to 2.4 mg/day, calculated as the amount of spermidine per adult.
  • the composition is preferably ingested 2 to 3 times per day.
  • the composition can be ingested, for example, every day, every 2nd day, every 3rd day, every 4th day, every 5th day, every week, every 2 weeks, every 3 weeks, or every 4 weeks. It is preferable to ingest the composition every day.
  • One embodiment of the present invention relates to a method for determining the effect of ingestion of a diamine and/or polyamine in a subject who has taken a diamine and/or polyamine (hereinafter referred to as the "determination method").
  • the method of assessment includes obtaining a measurement of a frailty index of a subject at a first time point before or during the ingestion of a diamine and/or polyamine, and obtaining a measurement of the same frailty index for the same subject at a second time point after the first time point during or after the ingestion of a diamine and/or polyamine.
  • the measurement at the second time point is equal to or greater than the measurement at the first time point, it suggests that the ingestion of diamine and/or polyamine was effective.
  • the measurement at the second time point is lower than the measurement at the first time point, it suggests that the ingestion of diamine and/or polyamine was not effective.
  • the frailty index is, for example, at least one selected from the group consisting of decreased skeletal muscle mass, decreased right arm muscle mass, decreased left arm muscle mass, decreased trunk muscle mass, decreased right leg muscle mass, decreased left leg muscle mass, decreased grip strength, decreased back muscle strength, and decreased leg strength.
  • Skeletal muscle mass and muscle mass by site can be measured, for example, using Inbody570 (Inbody Japan Co., Ltd.).
  • Grip strength can be measured, for example, using a digital grip strength meter (Takei Machinery Co., Ltd.).
  • Back strength can be measured, for example, using a digital back strength meter (Takei Machinery Co., Ltd.).
  • Leg strength can be evaluated, for example, using a five-time chair stand test.
  • the measurement value at the second time point being equal to or greater than the measurement value at the first time point means that when each measurement value is obtained multiple times at one time point, the measurement value at the second time point is equal to or greater than the value of the [average] - [2SD (standard deviation)] of the first measurement value, preferably equal to or greater than the value of the [average] - [1SD (standard deviation)] (in the above formula, "-" indicates subtraction).
  • Multiple times means, for example, three, four, or five times.
  • the measurement value at the second time point being lower than the measurement value at the first time point means that when each measurement value is obtained multiple times at one time point, the measurement value at the second time point is lower than the value of the [average] - [2SD (standard deviation)] of the first measurement value, preferably lower than the value of the [average] - [1SD (standard deviation)] (in the above formula, "-" indicates subtraction).
  • Multiple times means, for example, three, four, or five times.
  • test food a food containing polyamines
  • Test foods A and B were either capsules containing 1800 mg of polyamine (6 tablets) or placebo (6 tablets) containing 1800 mg of polyamine. Each test food was mixed with an excipient and placed in a dark-colored capsule so that the contents of the capsule were completely invisible from the outside.
  • Evaluation Items were as follows: ⁇ Muscle mass by region (right leg, left leg), grip strength, back muscle strength
  • Sample (information) and collection method Information was collected on each test day using the following methods.
  • Consent of the test subject Name of the person who consented, date of consent acquisition Background of the test subject: Age (date of birth), gender, etc.
  • Questionnaire at the time of the test (exercise and diet on the previous day, physical condition and diet on the day, etc.)
  • Test results 3-1 Efficacy evaluation (overall) Of the 60 study participants, two who dropped out for personal reasons and one whose intake rate was less than 70% were excluded, and the remaining 57 participants were included in the efficacy analysis. Table 2 shows the background of the subjects in the efficacy analysis.
  • polyamine intake showed a tendency for muscle mass in the left leg to increase. Furthermore, subgroup analysis of elderly people showed a significant increase in muscle mass in the left leg and a significant tendency for muscle mass in the right leg to increase, suggesting that the effect of strengthening leg muscles is stronger in elderly people. Furthermore, although the body part differed, polyamine intake showed a tendency for back muscle strength to increase, and subgroup analysis of elderly people showed a significant increase in grip strength, suggesting the possibility of an effect on strengthening muscles other than the legs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2024/034608 2023-09-29 2024-09-27 フレイルを予防、又は改善するためのジアミン、及び/又はポリアミンを含む組成物 Ceased WO2025070707A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025549163A JPWO2025070707A1 (cg-RX-API-DMAC7.html) 2023-09-29 2024-09-27

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-170359 2023-09-29
JP2023170359 2023-09-29

Publications (1)

Publication Number Publication Date
WO2025070707A1 true WO2025070707A1 (ja) 2025-04-03

Family

ID=95201699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/034608 Ceased WO2025070707A1 (ja) 2023-09-29 2024-09-27 フレイルを予防、又は改善するためのジアミン、及び/又はポリアミンを含む組成物

Country Status (2)

Country Link
JP (1) JPWO2025070707A1 (cg-RX-API-DMAC7.html)
WO (1) WO2025070707A1 (cg-RX-API-DMAC7.html)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506230A (ja) * 2017-12-20 2021-02-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法
WO2022061234A2 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Immunological effects of metabolites
JP2022537114A (ja) * 2019-06-20 2022-08-24 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 1種以上の同化アミノ酸による筋骨格への効果を増強するための組成物及び方法
WO2023182342A1 (ja) * 2022-03-22 2023-09-28 佐藤製薬株式会社 骨格筋増強剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021506230A (ja) * 2017-12-20 2021-02-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー オートファジーの誘導のためにオートファジー誘導因子と高タンパク質との組み合わせを使用する組成物及び方法
JP2022537114A (ja) * 2019-06-20 2022-08-24 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 1種以上の同化アミノ酸による筋骨格への効果を増強するための組成物及び方法
WO2022061234A2 (en) * 2020-09-21 2022-03-24 The Regents Of The University Of California Immunological effects of metabolites
WO2023182342A1 (ja) * 2022-03-22 2023-09-28 佐藤製薬株式会社 骨格筋増強剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAZAWA TOSHIKO , SHIZUO YAMADA: "Role of skeletal muscle homeostasis of functional food material", FOLIA PHARMACOLOGICA JAPONICA, vol. 155, no. 4, 1 January 2020 (2020-01-01), JP , pages 236 - 240, XP093297861, ISSN: 1347-8397, DOI: 10.1254/fpj19151 *

Also Published As

Publication number Publication date
JPWO2025070707A1 (cg-RX-API-DMAC7.html) 2025-04-03

Similar Documents

Publication Publication Date Title
JP7281031B2 (ja) 加齢に伴う持続的注意力低下の改善用の組成物
CN102647913B (zh) 用于促进血液循环和缓解手脚冰冷的、含有发酵茶提取物的组合物
JP7091344B2 (ja) アミロース分解活性および短鎖脂肪酸産生微生物の活性を促進するためのプレバイオティクス栄養補助食品
CN101983072B (zh) 矿物质吸收促进剂和缺铁性贫血改善剂或食物组合物
JP2019180364A (ja) 認知機能改善用食品組成物、認知機能改善剤、及び、これらの製造方法
JP2018058903A (ja) 成長ホルモン分泌促進剤
JP6301024B2 (ja) フィーカリバクテリウム属細菌増殖剤
US20180360899A1 (en) Agent for maintaining healthy obesity
EP4129404A1 (en) Muscle enhancer
JP2025088563A (ja) 脳機能低下を予防するための、又は脳機能を改善するためのジアミン、及び/又はポリアミンを含む組成物
JP7090864B2 (ja) 組成物
JP7675259B1 (ja) ストレス軽減用組成物
JPWO2005074961A1 (ja) 体脂肪調整剤
WO2025115964A1 (ja) ジアミン及び/又はポリアミンを含む組成物、並びに、その利用
WO2022270616A1 (ja) 筋損傷抑制用組成物
JP2019180412A (ja) 経口組成物
TWI890768B (zh) 體脂肪減低劑
JP2019176828A (ja) 経口組成物
JP6096439B2 (ja) 成長ホルモン分泌促進剤
KR20180067916A (ko) 천연물을 유효성분으로 함유하는 건강기능 식품 및 그 조성물
HK40049204A (en) Composition for improving cognitive function speed
JP2014051535A (ja) 鉄、カルシウム、又はマグネシウムの吸収を促進する方法
CN118947894A (zh) 一种阿胶组合物的制备方法及其应用
JP2022168204A (ja) 経口組成物
CN121369599A (zh) 一种人参黄芪饮品及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24872489

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025549163

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025549163

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE